Last reviewed · How we verify
Methylene Blue MMX® — Competitive Intelligence Brief
phase 3
Mitochondrial function enhancer / Antioxidant
Mitochondrial electron transport chain; cytochrome c oxidase
Neurology
Small molecule
Live · refreshed every 30 min
Target snapshot
Methylene Blue MMX® (Methylene Blue MMX®) — Cosmo Technologies Ltd. Methylene Blue MMX is a modified-release formulation of methylene blue that acts as a mitochondrial function enhancer and antioxidant to improve cognitive and neurological outcomes.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Methylene Blue MMX® TARGET | Methylene Blue MMX® | Cosmo Technologies Ltd | phase 3 | Mitochondrial function enhancer / Antioxidant | Mitochondrial electron transport chain; cytochrome c oxidase |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Mitochondrial function enhancer / Antioxidant class)
- Cosmo Technologies Ltd · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Methylene Blue MMX® CI watch — RSS
- Methylene Blue MMX® CI watch — Atom
- Methylene Blue MMX® CI watch — JSON
- Methylene Blue MMX® alone — RSS
- Whole Mitochondrial function enhancer / Antioxidant class — RSS
Cite this brief
Drug Landscape (2026). Methylene Blue MMX® — Competitive Intelligence Brief. https://druglandscape.com/ci/methylene-blue-mmx. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab